Stock Rating Upgrade
Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) improved in recent days. EYPT’s current Value Trend Rating is B and the prior Rating was C. Details supporting this higher rating are included in our next report.
Recent Price Action
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock rose modestly by 0.5% on 5/24/24. The stock closed at $11.16. However, trading volume in this advance was exceptionally low at 41% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -10.9% during the last week.
Current PriceTarget Research Rating
EYPT is expected to continue to be a modest Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
EyePoint Pharmaceuticals has a current Value Trend Rating of B (Positive). This VT Rating improved in recent days from C previously. The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. EyePoint Pharmaceuticals has a slightly negative Appreciation Score of 33 but a very high Power Rating of 90, with the Positive Value Trend Rating the result.
Be the first to comment